Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]Code Context
trigger_error($message, E_USER_DEPRECATED);
}
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.' $stackFrame = (int) 1 $trace = [ (int) 0 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php', 'line' => (int) 2421, 'function' => 'deprecationWarning', 'args' => [ (int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.' ] ], (int) 1 => [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 73, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) {}, 'type' => '->', 'args' => [ (int) 0 => 'catslug' ] ], (int) 2 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php', 'line' => (int) 610, 'function' => 'printArticle', 'class' => 'App\Controller\ArtileDetailController', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 3 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 120, 'function' => 'invokeAction', 'class' => 'Cake\Controller\Controller', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 4 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 94, 'function' => '_invoke', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(App\Controller\ArtileDetailController) {} ] ], (int) 5 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php', 'line' => (int) 235, 'function' => 'dispatch', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 6 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Http\BaseApplication', 'object' => object(App\Application) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 7 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php', 'line' => (int) 162, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 8 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\RoutingMiddleware', 'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 9 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php', 'line' => (int) 88, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 10 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\AssetMiddleware', 'object' => object(Cake\Routing\Middleware\AssetMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 11 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php', 'line' => (int) 96, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 12 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware', 'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 13 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 51, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 14 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php', 'line' => (int) 98, 'function' => 'run', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\MiddlewareQueue) {}, (int) 1 => object(Cake\Http\ServerRequest) {}, (int) 2 => object(Cake\Http\Response) {} ] ], (int) 15 => [ 'file' => '/home/brlfuser/public_html/webroot/index.php', 'line' => (int) 39, 'function' => 'run', 'class' => 'Cake\Http\Server', 'object' => object(Cake\Http\Server) {}, 'type' => '->', 'args' => [] ] ] $frame = [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 73, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) { trustProxy => false [protected] params => [ [maximum depth reached] ] [protected] data => [[maximum depth reached]] [protected] query => [[maximum depth reached]] [protected] cookies => [[maximum depth reached]] [protected] _environment => [ [maximum depth reached] ] [protected] url => 'latest-news-updates/drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474/print' [protected] base => '' [protected] webroot => '/' [protected] here => '/latest-news-updates/drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474/print' [protected] trustedProxies => [[maximum depth reached]] [protected] _input => null [protected] _detectors => [ [maximum depth reached] ] [protected] _detectorCache => [ [maximum depth reached] ] [protected] stream => object(Zend\Diactoros\PhpInputStream) {} [protected] uri => object(Zend\Diactoros\Uri) {} [protected] session => object(Cake\Http\Session) {} [protected] attributes => [[maximum depth reached]] [protected] emulatedAttributes => [ [maximum depth reached] ] [protected] uploadedFiles => [[maximum depth reached]] [protected] protocol => null [protected] requestTarget => null [private] deprecatedProperties => [ [maximum depth reached] ] }, 'type' => '->', 'args' => [ (int) 0 => 'catslug' ] ]deprecationWarning - CORE/src/Core/functions.php, line 311 Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421 App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73 Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51 Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]Code Context
trigger_error($message, E_USER_DEPRECATED);
}
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.' $stackFrame = (int) 1 $trace = [ (int) 0 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php', 'line' => (int) 2421, 'function' => 'deprecationWarning', 'args' => [ (int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.' ] ], (int) 1 => [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 74, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) {}, 'type' => '->', 'args' => [ (int) 0 => 'artileslug' ] ], (int) 2 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php', 'line' => (int) 610, 'function' => 'printArticle', 'class' => 'App\Controller\ArtileDetailController', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 3 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 120, 'function' => 'invokeAction', 'class' => 'Cake\Controller\Controller', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 4 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 94, 'function' => '_invoke', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(App\Controller\ArtileDetailController) {} ] ], (int) 5 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php', 'line' => (int) 235, 'function' => 'dispatch', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 6 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Http\BaseApplication', 'object' => object(App\Application) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 7 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php', 'line' => (int) 162, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 8 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\RoutingMiddleware', 'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 9 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php', 'line' => (int) 88, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 10 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\AssetMiddleware', 'object' => object(Cake\Routing\Middleware\AssetMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 11 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php', 'line' => (int) 96, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 12 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware', 'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 13 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 51, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 14 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php', 'line' => (int) 98, 'function' => 'run', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\MiddlewareQueue) {}, (int) 1 => object(Cake\Http\ServerRequest) {}, (int) 2 => object(Cake\Http\Response) {} ] ], (int) 15 => [ 'file' => '/home/brlfuser/public_html/webroot/index.php', 'line' => (int) 39, 'function' => 'run', 'class' => 'Cake\Http\Server', 'object' => object(Cake\Http\Server) {}, 'type' => '->', 'args' => [] ] ] $frame = [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 74, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) { trustProxy => false [protected] params => [ [maximum depth reached] ] [protected] data => [[maximum depth reached]] [protected] query => [[maximum depth reached]] [protected] cookies => [[maximum depth reached]] [protected] _environment => [ [maximum depth reached] ] [protected] url => 'latest-news-updates/drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474/print' [protected] base => '' [protected] webroot => '/' [protected] here => '/latest-news-updates/drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474/print' [protected] trustedProxies => [[maximum depth reached]] [protected] _input => null [protected] _detectors => [ [maximum depth reached] ] [protected] _detectorCache => [ [maximum depth reached] ] [protected] stream => object(Zend\Diactoros\PhpInputStream) {} [protected] uri => object(Zend\Diactoros\Uri) {} [protected] session => object(Cake\Http\Session) {} [protected] attributes => [[maximum depth reached]] [protected] emulatedAttributes => [ [maximum depth reached] ] [protected] uploadedFiles => [[maximum depth reached]] [protected] protocol => null [protected] requestTarget => null [private] deprecatedProperties => [ [maximum depth reached] ] }, 'type' => '->', 'args' => [ (int) 0 => 'artileslug' ] ]deprecationWarning - CORE/src/Core/functions.php, line 311 Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421 App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74 Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51 Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]Code Contextif (Configure::read('debug')) {
trigger_error($message, E_USER_WARNING);
} else {
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-trace').style.display = (document.getElementById('cakeErr68022f255b980-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68022f255b980-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-code').style.display = (document.getElementById('cakeErr68022f255b980-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-context').style.display = (document.getElementById('cakeErr68022f255b980-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68022f255b980-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr68022f255b980-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> &quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> &quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 24295, 'metaTitle' => 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'metaKeywords' => 'medicines,Access to Medicines,Health', 'metaDesc' => ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...', 'disp' => '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">&quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">&quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> &quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> &quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {}, (int) 2 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 24295 $metaTitle = 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh' $metaKeywords = 'medicines,Access to Medicines,Health' $metaDesc = ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...' $disp = '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">&quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">&quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh | Im4change.org</title> <meta name="description" content=" -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">"MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">"Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $maxBufferLength = (int) 8192 $file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php' $line = (int) 853 $message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]Code Context$response->getStatusCode(),
($reasonPhrase ? ' ' . $reasonPhrase : '')
));
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-trace').style.display = (document.getElementById('cakeErr68022f255b980-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68022f255b980-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-code').style.display = (document.getElementById('cakeErr68022f255b980-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-context').style.display = (document.getElementById('cakeErr68022f255b980-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68022f255b980-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr68022f255b980-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> &quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> &quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 24295, 'metaTitle' => 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'metaKeywords' => 'medicines,Access to Medicines,Health', 'metaDesc' => ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...', 'disp' => '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">&quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">&quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> &quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> &quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {}, (int) 2 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 24295 $metaTitle = 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh' $metaKeywords = 'medicines,Access to Medicines,Health' $metaDesc = ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...' $disp = '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">&quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">&quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh | Im4change.org</title> <meta name="description" content=" -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">"MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">"Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $reasonPhrase = 'OK'header - [internal], line ?? Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148 Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]Notice (8): Undefined variable: urlPrefix [APP/Template/Layout/printlayout.ctp, line 8]Code Context$value
), $first);
$first = false;
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-trace').style.display = (document.getElementById('cakeErr68022f255b980-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68022f255b980-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-code').style.display = (document.getElementById('cakeErr68022f255b980-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68022f255b980-context').style.display = (document.getElementById('cakeErr68022f255b980-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68022f255b980-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr68022f255b980-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> &quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> &quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 24295, 'metaTitle' => 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'metaKeywords' => 'medicines,Access to Medicines,Health', 'metaDesc' => ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...', 'disp' => '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">&quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">&quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> &quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> &quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {}, (int) 2 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 24295 $metaTitle = 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh' $metaKeywords = 'medicines,Access to Medicines,Health' $metaDesc = ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...' $disp = '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled &quot;Drug Price Ceiling&quot;, states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. &quot;Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients,&quot; says the report. The second report, named &quot;Access to Medicines&quot;, expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the &quot;pharmacy of the global south&quot;, India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">&quot;MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO,&quot; says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of &quot;a substantial inessential, irrational and unsafe medicines market&quot;, but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, &quot;Access to Medicines&quot;, has noted that the irrational use of medicines is a big concern. &quot;Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant,&quot; says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">&quot;Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products,&quot; said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh | Im4change.org</title> <meta name="description" content=" -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">"MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">"Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $cookies = [] $values = [ (int) 0 => 'text/html; charset=UTF-8' ] $name = 'Content-Type' $first = true $value = 'text/html; charset=UTF-8'header - [internal], line ?? Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181 Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
<head>
<link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> "MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> "Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 24295, 'metaTitle' => 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'metaKeywords' => 'medicines,Access to Medicines,Health', 'metaDesc' => ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...', 'disp' => '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">"MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">"Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 24295, 'title' => 'Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh', 'subheading' => '', 'description' => '<div align="justify"> -Down to Earth </div> <p align="justify"> <br /> <em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em> </p> <p align="justify"> Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. </p> <p align="justify"> One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use. </p> <p align="justify"> The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. </p> <p align="justify"> <em>The pricing dilemma</em> </p> <p align="justify"> Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. </p> <p align="justify"> "MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. </p> <p align="justify"> Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year. </p> <p align="justify"> <em>Irrational prescription and use a matter of concern</em> </p> <p align="justify"> The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report. </p> <p align="justify"> It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. </p> <p align="justify"> "Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. </p> <p align="justify"> *** </p> <p align="justify"> <strong>Recommendations of the reports<br /> </strong> </p> <p align="justify"> <strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>', 'credit_writer' => 'Down to Earth, 10 March, 2014, http://www.downtoearth.org.in/content/drug-pricing-policies-bent-favour-pharma-industry-allege-health-experts', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-pricing-policies-bent-to-favour-pharma-industry-allege-health-experts-jyotsna-singh-24474', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 24474, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {}, (int) 2 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 24295 $metaTitle = 'LATEST NEWS UPDATES | Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh' $metaKeywords = 'medicines,Access to Medicines,Health' $metaDesc = ' -Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs...' $disp = '<div align="justify">-Down to Earth</div><p align="justify"><br /><em>Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports</em></p><p align="justify">Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs.</p><p align="justify">One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use.</p><p align="justify">The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs.</p><p align="justify"><em>The pricing dilemma</em></p><p align="justify">Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive.</p><p align="justify">"MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share.</p><p align="justify">Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year.</p><p align="justify"><em>Irrational prescription and use a matter of concern</em></p><p align="justify">The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report.</p><p align="justify">It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public.</p><p align="justify">"Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent.</p><p align="justify">***</p><p align="justify"><strong>Recommendations of the reports<br /></strong> </p><p align="justify"><strong> </strong>The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years<br /> The current market-based formula is not expected to reduce the prices of medicines significantly, it is strongly recommended that cost-based formula be reinstated.<br /> The department of pharmaceuticals should be transferred from Union Ministry of Chemicals and Fertilisers to the Union Ministry of Health and Family Welfare<br /> The National List of Essential Medicines should be revised to omit outdated drugs and include newer, more effective ones. It should also address need of different essential medicines of different states.<br /> </p>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'
include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
![]() |
Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh |
-Down to Earth
Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released by Delhi-based organisations, Public Health Foundation of India (PHFI) and Institute for Studies in Industrial Development, last Thursday, pointed towards policy gaps in pricing of drugs. One of the reports, titled "Drug Price Ceiling", states that coverage under DPCO, at present, is limited to only about 17 per cent of the drugs prescribed and promoted in the country. This leaves nearly 82 per cent of the medicines out of ambit of the policy, thus resulting in high prices. "Clearly the interests of the pharmaceutical industry have received precedence over the interest of patients," says the report. The second report, named "Access to Medicines", expresses concern over high prices of drugs and their irrational use. The reports together highlights the fact that despite being the "pharmacy of the global south", India has been creating a situation wherein its own citizens have to pay huge amounts of money to buy drugs. The pricing dilemma Despite criticism from several quarters, DPCO had used market-based pricing (MBP) formula to determine prices of medicines, instead of cost-plus pricing (CBP) formula. In CBP, price of a medicine has to be calculated on the basis of cost of manufacturing and pre-determined profit. MBP, on the other hand, is calculated taking average of top selling brands, which in most cases are expensive. "MBP has been unable to bring down the prices. Manufacturers earn money which is 10 times the cost of production of medicines. Our calculations show that their profit has hardly come down after the implementation MBP, which means that consumers have not benefitted from DPCO," says Sakthivel Selvaraj, a leading author of both the reports and a member of PHFI. The PHFI report shows that the profit of manufacturers has decreased by less than two per cent of the total market share. Critisicing DPCO, the report says that the policy provides pharmaceutical companies several ways to escape price control. It not only permits the presence of "a substantial inessential, irrational and unsafe medicines market", but also encourages its growth by allowing a 10 per cent increase in prices each year. Irrational prescription and use a matter of concern The second report, "Access to Medicines", has noted that the irrational use of medicines is a big concern. "Not only are hazardous and inessential medicines being produced and sold in the country but irrational prescription, dispensing and use of these medicines is also rampant," says the report. It also notes that despite being one of the leading producers of vaccines in the world, India has the maximum child mortality rate. This is due to poor outreach under the Universal Immunisation Programme (UIP). Moreover, private companies in the pharmaceutical industry are successfully able to sell non-UIP vaccines and combination vaccines to the general public. "Combination vaccines and medicines (which contain two or more active pharmaceutical ingredients) do not fall in the purview of DPCO. This has become an escape route for the manufacturers to avoid legal hurdles in fixing prices for their products," said Selvaraj. As many as 47 per cent drugs in India today are fixed dose combination drugs. Though there is no exact data, the figure usually falls in the range of five-12 per cent. *** Recommendations of the reports The current spending on medicines by the government (both Centre and state) is a meagre 0.1 per cent of the GDP. This needs to be scaled up to at least 0.5 per cent of the GDP in the next five years |